{'fraction_non_alphanumeric': 0.044859813084112146, 'fraction_numerical': 0.04766355140186916, 'mean_word_length': 4.666666666666667, 'pattern_counts': {'":': 0, '<': 1, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Oral desmopressin treatment of central diabetes insipidus in children

To assess the efficacy of treatment with oral desmopressin (DDAVP), 20 patients, aged 5–20 y, with central diabetes insipidus were studied during 3 d of hospitalization and for 3 months at the outpatient clinic. At baseline the median rate of diuresis was 12. 7 ml kg‐1 h‐1. Urinary output decreased significantly under treatment with an increase in urinary osmolality, normalization of plasma osmolality and absence of nocturia. Patients were discharged from hospital with a median dose of 500μg d‐1 (100–1200μg d‐1). An adjustment in dosage was necessary in seven patients during follow‐up, resulting in a final dose of 600μg d‐1. Body weight and DDAVP doses (r= 0. 75, p= 0. 001) and body surface and DDAVP doses (r= 0. 72, p < 0. 001) were significantly correlated. The average dosage was 474 ± 222μg m‐2 d‐1 (mean ± SD). The oral DDAVP treatment remained effective during the 3 months of follow‐up. This therapy offers an alternative for the treatment of central diabetes insipidus in children.